Imunofan Nazal Spray. 45mkg / dose vials 40doz

Description

Composition
Active substance:
1 dose contains: 1 dose contains alpha-arginyl-lysyl-aspartyl-valyl-tyrosyl-arginine, 45 mcg.
Excipients:
Glycine 5 mg sodium chloride 0.7 mg benzalkonium chloride 0.014 mg disodium edetate 0.007 mg purified water to 0.14 ml.
Description:
Transparent or slaboopalestsiruyuschaya colorless or slightly yellowish liquid. Allowed a faint odor.
Product form:
Imunofan®, nasal spray dosage 45 .mu.g / dose. 40 doses in plastic bottles with a capacity of 10 ml. The vials were sealed with lids provided with a dosing pump with plastic housing, the nozzle and the protective cap or similar metering device. One vial together with instructions for use placed in a pile of cardboard.
Contraindications
Hypersensitivity, children up to 2 years.
Dosage
45 ug / dose
Indications
Is used in adults and children over 2 years of age for the prevention and treatment of immune deficiency and toxic states, acute and chronic infectious and inflammatory diseases.
Interaction with other drugs
It increases the effectiveness of other types of drug therapy: the use of imunofana helps to overcome resistance to glucocorticosteroid therapy. Appointment imunofana possibly in combination with the steroid and non-steroidal anti-inflammatory drugs.
pharmachologic effect
Pharmacological group:
Immunomodulatory agent.
Pharmacological properties:
The drug has immunoregulatory, detoxification, hepatoprotective action and causes inactivation of free radical and peroxy compounds. Pharmacological action is based on three main effects: the adjustment of the immune system to restore the balance of oxidation reactions of the organism and an antioxidant for inhibiting multidrug resistance mediated transmembrane transport proteins cell pump. Effect of the drug begins to develop for 2 – 3 hours (fast phase) and lasts up to 4 months (medium and slow phase). During fast phase (duration – 2 – 3 days) appears primarily detoxifying effect – enhanced antioxidant protection of the organism by stimulating the production of ceruloplasmin, lactoferrin, catalase activity; preparation normalizes the peroxidation of lipids, phospholipids inhibits disintegration of cell membranes and the synthesis of arachidonic acid, followed by reduction of blood cholesterol levels and the production of inflammation mediators. When toxic and infectious damage of liver drug prevents cytolysis and reduces the activity of transaminases and bilirubin levels in the serum. During the middle phase (starting 2-3 days, the length – up to 7-10 days) is amplified reactions phagocytosis and intracellular destruction of bacteria and viruses. During the slow phase (begins to develop at 7 – 10 day duration of up to 4 months) is shown immunoregulatory effect of the drug – a remedy of cellular and humoral immunity. During this period, there is renewal immunoregulatory index, there is an increase in the production of specific antibodies. Effect on the production of specific antiviral or antibacterial antibodies equivalent to the action of therapeutic vaccines. Unlike the latter drug has no significant effect on the production of reaginic IgE class antibodies and reinforces the immediate hypersensitivity reaction. Imunofan stimulates the formation of IgA deficiency when it is congenital. Imunofan effectively inhibits multidrug resistance of tumor cells and increases their susceptibility to chemotherapeutic agents.
Pregnancy and breast-feeding
You should not use the drug during pregnancy complicated by Rh-conflict. Pregnancy and lactation are used only if the expected benefit to the mother outweighs the potential risk to the fetus and child.
Conditions of supply of pharmacies
By prescription.
side effects
The individual intolerance.
special instructions
The drug does not affect the ability to drive vehicles, machinery. As a result of activation of phagocytosis may transient exacerbation of chronic inflammation foci supported due to the persistence of viral or bacterial antigens.
Storage conditions
In the dark place at a temperature of 2 C to 10 C. Keep out of reach of children.
Dosing and Administration
Intranasally. When using a vial to be held upright, spray up. To remove a protective cap from the dispenser. Before first use, fill the dosing pump by pressing the wide bezel sprayer 3-4 times. Insert spray to the nasal passage in the vertical position of the head. Momentary push wide rim atomizer until it stops. The single dose of the preparation contains 50 mg imunofana. The daily dose should not exceed 200 micrograms.
In the treatment of acute and chronic infectious inflammatory diseases associated symptoms of intoxication and immunodeficiency, imunofan appoint 1 dose (50 mcg) in each nostril two times a day, every day for 10 – 15 days.
Opportunistic infections (cytomegalovirus, and herpes infection, toxoplasmosis, chlamydia, pneumocystis, cryptosporidiosis): 1 dose (50 mcg) in each nostril 2 times a day, every day, a course of treatment 10 – 15 days. If necessary, possible repetition rate in 2-4 weeks
In chronic viral hepatitis and chronic brucellosis: 1 dose (50 mcg) in each nostril 1 times a day, every day, a course of treatment 10 – 15 days, in order to prevent recurrence should be repeated courses within 4 – 6 months.
In the treatment of cancer patients in Scheme radical combined treatment (chemo-radiotherapy and surgery): 1 dose (50 mcg) in each nostril once a day 1, daily for 8-10 days before chemo-radiotherapy and surgery with followed by continuation of the course for the entire treatment period.
In patients with advanced neoplastic process (III – IV stages) different localization in terms of integrated therapy or symptomatic: 1 dose (50 mcg) in each nostril once a day 1, daily for 8-10 days. If necessary, and there are significant phenomena of toxicity is recommended repeat the course.
Information
Appearance may differ from that depicted in the picture. There are contraindications. You need to read the manual or consult with a specialist